CD274 and ovarian carcinoma: Recent clinical trials on ovarian cancer, including JAVELIN Ovarian 100 (NCT02718417) and JAVELIN Ovarian 200 (NCT02580058), demonstrated that the PD-L1 inhibitor avelumab, either as monotherapy or in combination with chemotherapy, did not significantly improve progression-free survival (PFS) or overall survival (OS) compared to chemotherapy alone (72, 73).